Business
Halberd Corp. VITA-SHIELD-MAX(TM) Available - Buy Now!
Halberd Corp. VITA-SHIELD-MAX(TM) Available - Buy Now!.
About this update from Halberd Corp.
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / August 18, 2021 / Halberd Corporation's (OTC PINK:HALB) Nutraceutical product, Vita-Shield-MaxTM is now available on www.vitashieldmax.com. Vita-Shield-MaxTM is a specially formulated Nutraceutical to help maintain a healthy immune system.William A. Hartman, Halberd's Chairman, President & CEO, stated, "Halberd Corporation's scientists put extensive research into the precise formulation of this neutraceutical product designed specifically to maintain a healthy immune system based on publications, including numerous medical articles and immune bio-scientificresearch. As published earlier, these articles have been compiled into a single 120-page document for convenience. The release of Halberd's Immune Support is timely, coinciding with the resurgence of Covid, in mutant forms prompting many to seek immediate potential immunity support via booster shot alternatives. We believe that our VITA-SHIELD-MAXTM nutraceutical is a quality product at a reasonable price that meets the market demands. Halberd Corporation is committed to meeting total medical needs, including the creation of a new Nutraceutical Division of our company and via our continuing research with two State University partners and a private firm into finding potential effective treatments for Covid, Alzheimer's Disease, PTSD, and Chronic Traumatic Encephalopathy and other diseases."To get the latest news on Halberd's exciting medical developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.(https://halberdcorporation.com/contact-us/)For more information please contact:William A. [email protected];[email protected]://www.halberdcorporation.comTwitter:@HalberdCAbout Halberd Corporation.Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.Safe Harbor NoticeCertain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Ac...